Calcilytics (NPSP790 & NPSP795)

About NPS Pharma

Calcilytics are small-molecule antagonists of the calcium receptor.  Initially developed to stimulate parathyroid hormone secretion and bone formation for the treatment of osteoporosis and other bone metabolism disorders, they have been shown to increase serum calcium and decrease urinary calcium excretion in a Phase 2 study of patients with osteoporosis.  Calcilytics could be a novel treatment for disorders involving increased calcium receptor activity.